News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

May 11, 2023

Summary Toggle aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference

SAN DIEGO , May 11, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.
May 9, 2023

Summary Toggle aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis currently enrolling in the U.S. , Europe and Japan . Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to initiate in the third quarter of 2023.
Apr 17, 2023

Summary Toggle aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting

Findings demonstrate effects of ATYR2810 in models of certain forms of lung and kidney cancers SAN DIEGO , April 17, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
Mar 30, 2023

Summary Toggle aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases

Paper highlights efzofitimod as a first-in-class biologic with significant anti-inflammatory properties SAN DIEGO , March 30, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its
Mar 21, 2023

Summary Toggle aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution

Findings confirm LTBP1, a key regulator of TGF-β, as binding partner for tRNA synthetase DARS fragment ATYR0101 Data indicates ATYR0101 may have therapeutic potential for fibrotic pathologies SAN DIEGO , March 21, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
Mar 20, 2023

Summary Toggle aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies

Panel discussion to be held on Saturday, March 25 at 12:00pm ET / 11:00am CT / 9:00am PT. SAN DIEGO , March 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its
Mar 9, 2023

Summary Toggle aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S. , Europe and Japan . Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to begin in 2023. February 2023 follow-on common stock offering of approximately $52.0 million
Mar 8, 2023

Summary Toggle aTyr Pharma to Present at March Investor Conferences

SAN DIEGO , March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at two upcoming investor
Mar 2, 2023

Summary Toggle aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

Management to host conference call and webcast on March 9th at 5:00 pm EST / 2:00 pm PST SAN DIEGO , March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
Mar 1, 2023

Summary Toggle aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application

Proof-of-Concept study in SSc-ILD expected to begin in 2023. Efzofitimod has been granted U.S. FDA orphan drug designation for SSc and Fast Track designation for SSc-ILD. SAN DIEGO , March 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company